Top HHS pharmaceutical preparation manufacturing contractors
In the 12 months ending Oct 5, 2026, the Department of Health and Human Services obligated $777.8M in net prime contract dollars under NAICS 325412, down 30.4% from $1.1B in the preceding 12 months. 63 prime contractors received positive obligations, and 9 of them accounted for 80% of that spend.
Prime contracts funded by the Department of Health and Human Services. Latest 12 months: Oct 6, 2025 to Oct 5, 2026. Source: USAspending.gov.
Obligations by fiscal year
Net prime contract obligations by federal fiscal year (October to September).
Top HHS contractors for NAICS 325412
Ranked by positive obligations in the latest 12 months. Share is of all positive obligations in this market.
| # | Contractor | Latest 12 mo | Prior 12 mo | Share | Rank change |
|---|---|---|---|---|---|
| 1 | Emergent Biosolutions Canada Inc | $118.3M | $114.3M | 14.3% | ▲ 4 |
| 2 | Phlow Corp. | $105.3M | $8.4M | 12.7% | ▲ 18 |
| 3 | Bavarian Nordic a/S | $97.0M | $143.6M | 11.7% | — |
| 4 | Mckesson Corporation | $80.2M | $196.4M | 9.7% | ▼ 2 |
| 5 | DLA Troop Support | $68.3M | $102.6M | 8.3% | ▲ 1 |
| 6 | Fresenius Kabi, LLC | $57.7M | $86.3M | 7.0% | ▲ 1 |
| 7 | Mckesson Specialty Distribution LLC | $51.1M | $61.5M | 6.2% | ▲ 2 |
| 8 | Partner Therapeutics, Inc. | $50.0M | $39.1M | 6.0% | ▲ 5 |
| 9 | Glaxosmithkline, LLC | $36.3M | $9.1M | 4.4% | ▲ 10 |
| 10 | Usantibiotics LLC | $30.0M | $0 | 3.6% | New |
| 11 | Chartwell RX LLC | $27.2M | $114.8M | 3.3% | ▼ 7 |
| 12 | D'S Ventures, LLC | $18.6M | $0 | 2.3% | New |
| 13 | Baxter Healthcare Corporation | $14.5M | $4.4M | 1.8% | ▲ 11 |
| 14 | Rafa Laboratories Ltd | $12.4M | $20.9M | 1.5% | — |
| 15 | Heyltex Corporation | $8.1M | $8.1M | 1.0% | ▲ 6 |
What changed in the last 12 months
Contractors with the largest change in reported obligations versus the preceding 12 months.
Largest gains
- Genentech USA, Inc−$314.4M → −$187 (+$314.4M) · no latest-period obligations
- Phlow Corp.$8.4M → $105.3M (+$96.9M) · now #2
- Usantibiotics LLC$0 → $30.0M (+$30.0M) · now #10
Largest declines
- Alvogen, Inc.$227.7M → $0 (−$227.7M) · no latest-period obligations
- Mckesson Corporation$196.4M → $80.2M (−$116.2M) · now #4
- Altitude Technologies Inc.$47.8M → −$47.8M (−$95.6M) · no latest-period obligations
New to this market
16 contractors received their first obligations in this market (since FY2022) during the latest 12 months. The largest:
| Contractor | First obligation | Latest 12 mo |
|---|---|---|
| Usantibiotics LLC | May 27, 2026 | $30.0M |
| D'S Ventures, LLC | Sep 30, 2026 | $18.6M |
| Accord Biopharma, Inc. | Mar 18, 2026 | $7.6M |
| Hikma Pharmaceuticals USA Inc. | Sep 30, 2026 | $7.5M |
| Southernbelle Room, LLC | Sep 30, 2026 | $6.2M |
| Serb Medical Solutions Inc. | Aug 12, 2026 | $1.2M |
| Research Triangle Institute | Aug 5, 2026 | $416K |
| Paragon Enterprises Inc | Sep 30, 2026 | $238K |
Where the money comes from
Funding sub-agencies within the Department of Health and Human Services, latest 12 months. The funding organization can differ from the office that runs the requirement.
| Funding sub-agency | Latest 12 mo | Prior 12 mo | Change |
|---|---|---|---|
| Office of Assistant Secretary for Preparedness and Response | $565.1M | $742.7M | Down $177.6M (23.9%) |
| Indian Health Service | $84.8M | $201.6M | Down $116.8M (57.9%) |
| National Institutes of Health | $74.5M | $108.8M | Down $34.2M (31.5%) |
| Centers for Disease Control and Prevention | $51.4M | $61.6M | Down $10.2M (16.6%) |
| Office of the Assistant Secretary for Financial Resources | $1.5M | $0 | New |
| Office of the Assistant Secretary for Administration | $390K | $1.8M | Down $1.4M (78.5%) |
Potential recompetes
Large awards in this market whose current period of performance ends in the next 18 months. Treat these as research leads: options, extensions, and follow-on vehicles often change the timing.
| Award | Incumbent | Obligated | Current end |
|---|---|---|---|
| 75A50120C00092 | Phlow Corp. US BASED ADVANCED API MANUFACTURING. BASE PERIOD FUNDING FOR US BASED ADVANCED MANUFACTURING OF COVID-19 ESSENTIAL MEDICINES AND FUTURE THREATS. | $342.4M | Jan 13, 2027 |
| 75D30123C17978 | Mckesson Specialty Distribution LLC CENTRALIZED VACCINE DISTRIBUTION | $203.9M | Jan 31, 2027 |
| 75A50323F80027 | Partner Therapeutics, Inc. LEUKINE 250MCG VIL INJ (5PKG) | $133.5M | Mar 29, 2027 |
| 75A50119C00075 | Emergent Biosolutions Canada Inc BOTULISM ANTITOXIN | $270.9M | Mar 30, 2027 |
| 75A50119C00037 | Emergent Biosolutions Canada Inc VIGIV BUY AND ASSOCIATED SERVICES | $287.5M | Mar 30, 2027 |
| 75N98026C00026 | DLA Troop Support PHARMACEUTICALS AND RELATED SUPPLIES UNITED STATES DEPARTMENT OF DEFENSE:1133869 [26-003472] | $77.4M | Apr 9, 2027 |
| 75A50325F80009 | Chartwell RX LLC DOXYCYCLINE HYCLATE 100 MG ORAL TABLETS | $144.6M | Jun 22, 2027 |
| 75A50325F80014 | Exelan Pharmaceuticals Inc OSELTAMIVIR PHOSPHATE 75MG CAPSULES (NDC: 76282-0704-45); 10 CT. BLISTERS PACKS AND OSELTAMIVIR PHOSPHATE 30MG CAPSULES (NDC: 76282-0702-45); 10 CT. BLISTERS PACKS. | $74.1M | Jun 29, 2027 |
| 75A50325F80013 | Alvogen, Inc. OSELTAMIVIR PHOSPHATE 75MG CAPSULES (NDC: 47781-470-13); 10 CT. BLISTERS PACKS AND OSELTAMIVIR PHOSPHATE 30MG CAPSULES (NDC: 47781-468-13); 10 CT. BLISTERS PACKS. | $227.7M | Jun 29, 2027 |
| HHSO100201700019C | Bavarian Nordic a/S | $882.1M | Sep 26, 2027 |
Common questions
Who are the top HHS contractors for NAICS 325412?
In the latest 12 months, Emergent Biosolutions Canada Inc ($118.3M), Phlow Corp. ($105.3M), Bavarian Nordic a/S ($97.0M) received the most HHS obligations for pharmaceutical preparation manufacturing.
How concentrated is this market?
The eight largest primes held 76.0% of positive obligations, and Emergent Biosolutions Canada Inc alone held 14.3%. 16 contractors won their first obligations in this market during the latest 12 months.
Are any large HHS NAICS 325412 contracts ending soon?
10 of the largest awards in this market reach their current end date in the next 18 months. The first is 75A50120C00092 (Phlow Corp., $342.4M obligated), ending Jan 13, 2027. An end date is a research lead, not a confirmed recompete: options and extensions often move it.
Related markets
NAICS 325412 across all agencies
VA · NAICS 325412
$11.1BDOJ · NAICS 325412
$200.6MDoD · NAICS 325412
$64.7MFigures are net obligations on prime contracts (award types A–D) from USAspending.gov, grouped by funding agency and the NAICS code on each award. Net obligations include deobligations and corrections, so they can differ from positive-obligation totals. See methodology.
Ready to connect your pursuit work?
GovEagle gives BD directors, capture managers, and proposal teams one AI workspace from pipeline through proposal, with CMMC/FedRAMP Certified compliance built in.